

FIGURE 1





FIGURE 2



208220* 9/198007

FIGURE 3




FIGURE 4





FIGURE 5

TFPI Peptide Inhibition of HUVEC Proliferation
bFGF vs VEGF



10086176-022602

FIGURE 6

TFPI Peptide Inhibition of Tumor Cells




FIGURE 7

Inhibition of RAP Binding to Immobilized sVLDLr1-8
JFR-24 August 2001






FIGURE 8

TFPI Peptide Inhibition of Huvec
Effect of VLDLr Antibody



10086176.022806
208220.94758001

FIGURE 9

Inhibition of LLC Metastases by TFPI Peptide




FIGURE 10

SEQ ID NO: 1

Lys	Gln	Glu	Cys	Leu	Arg	Ala	Cys	Lys	Lys		
Gly	Phe	Ile	Gln	Arg	Ile	Ser	Lys	Gly	Gly	Lev	Ile
Lys	Thr	Lys	Arg	Lys	Arg	Lys	Lys	Gln	Arg	Val	Lys
Ile	Ala	Tyr	Glu	Glu	Ile	Phe	Val	Lys	Asn	Met	

SEQ ID NO: 2

Ile	Ser	Lys	Gly	Gly	Leu	Ile					
Lys	Thr	Lys	Arg	Lys	Arg	Lys	Lys	Gln	Arg	Val	Lys
Ile	Ala	Tyr	Glu	Glu	Ile	Phe	Val	Lys	Asn	Met	

SEQ ID NO: 3

Lys	Thr	Lys	Arg	Lys	Arg	Lys	Lys	Gln	Arg	Val	Lys
Ile	Ala	Tyr	Glu	Glu	Ile	Phe	Val	Lys	Asn	Met	

SEQ ID NO: 4

Lys	Lys	Lys	Lys	Lys	Met	Phe	Lys	Leu	Arg	Phe	Ala
Ser	Arg	Ile	Arg	Lys	Ile	Arg	Lys	Lys	Gln	Phe	

10886175.0222002

FIGURE 11

Asp	Ser	Glu	Glu	Asp	Glu	Glu	His	Thr	Ile	Ile	Thr	Asp	Thr	Glu	Leu
1				5					10					15	
Pro	Pro	Leu	Lys	Leu	Met	His	Ser	Phe	Cys	Ala	Phe	Lys	Ala	Asp	Asp
		20						25					30		
Gly	Pro	Cys	Lys	Ala	Ile	Met	Lys	Arg	Phe	Phe	Phe	Asn	Ile	Phe	Thr
		35					40					45			
Arg	Gln	Cys	Glu	Glu	Phe	Ile	Tyr	Gly	Gly	Cys	Glu	Gly	Asn	Gln	Asn
	50					55					60				
Arg	Phe	Glu	Ser	Leu	Glu	Glu	Cys	Lys	Lys	Met	Cys	Thr	Arg	Asp	Asn
65					70					75					80
Ala	Asn	Arg	Ile	Ile	Lys	Thr	Thr	Leu	Gln	Gln	Glu	Lys	Pro	Asp	Phe
				85					90					95	
Cys	Phe	Leu	Glu	Glu	Asp	Pro	Gly	Ile	Cys	Arg	Gly	Tyr	Ile	Thr	Arg
			100					105					110		
Tyr	Phe	Tyr	Asn	Asn	Gln	Thr	Lys	Gln	Cys	Glu	Arg	Phe	Lys	Tyr	Gly
		115					120					125			
Gly	Cys	Leu	Gly	Asn	Met	Asn	Asn	Phe	Glu	Thr	Leu	Glu	Glu	Cys	Lys
	130					135					140				
Asn	Ile	Cys	Glu	Asp	Gly	Pro	Asn	Gly	Phe	Gln	Val	Asp	Asn	Tyr	Gly
145					150					155					160
Thr	Gln	Leu	Asn	Ala	Val	Asn	Asn	Ser	Leu	Thr	Pro	Gln	Ser	Thr	Lys
				165					170					175	
Val	Pro	Ser	Leu	Phe	Glu	Phe	His	Gly	Pro	Ser	Trp	Cys	Leu	Thr	Pro
			180					185					190		
Ala	Asp	Arg	Gly	Leu	Cys	Arg	Ala	Asn	Glu	Asn	Arg	Phe	Tyr	Tyr	Asn
		195					200					205			
Ser	Val	Ile	Gly	Lys	Cys	Arg	Pro	Phe	Lys	Tyr	Ser	Gly	Cys	Gly	Gly
	210					215					220				
Asn	Glu	Asn	Asn	Phe	Thr	Ser	Lys	Gln	Glu	Cys	Leu	Arg	Ala	Cys	Lys
225					230					235					240
Lys	Gly	Phe	Ile	Gln	Arg	Ile	Ser	Lys	Gly	Gly	Leu	Ile	Lys	Thr	Lys
				245					250					255	
Arg	Lys	Arg	Lys	Lys	Gln	Arg	Val	Lys	Ile	Ala	Tyr	Glu	Glu	Ile	Phe
			260					265					270		
Val	Lys	Asn	Met												
		275													

10066175-022802


[illegible][illegible]

208220 9/1980

Figure 13 (a-c)


5 μ M TFPI

C-Terminal Peptide




20 μ M TFPI

C-Terminal Peptide



50 μ M TFPI


C-Terminal Peptide



208220 9/19/01
Figure 14 (a-d)


20 μ M TFPI

C-Terminal Peptide




20 μ M TFPI


C-Terminal Peptide
+ Ab



Control + Ab



Control



TFPI Peptide + VLDL Antibody

